Your study ran. The product may well have worked. However, the primary endpoint was not met. The sample may have been too small. Or the measurement was inconsistent across sites. Or the effect size assumed in the power calculation was borrowed from a pharmaceutical dose with no relation to your formulation. The study is now a cost rather than an asset.

This article covers the nutraceutical clinical trial design failures that cause studies to miss their endpoints. It explains why they are so common and what well-designed studies do differently.

Key takeaways

• An estimated 50% of clinical trials fail to meet their primary endpoints. For nutraceutical studies, the failure rate is often higher. In many cases, the product is not the problem. The nutraceutical clinical trial design is.
• The most common failure is endpoint selection. The chosen endpoint is often not sensitive enough to detect the effect the product can realistically produce at the dose used.
• Sample size calculations that borrow effect size assumptions from pharmaceutical studies routinely underpower nutraceutical trials. Supplement effects are typically smaller and require larger samples to detect reliably.
• Eligibility criteria that are too broad produce heterogeneous populations where the treatment signal is diluted. Criteria that are too restrictive make recruitment slow and leave the study underpowered by attrition.
• Operational inconsistency: different sites measuring endpoints differently, missing data, and non-compliant participants cause data pooling problems that are hard to resolve at analysis.
• Good nutraceutical clinical trial design starts with the claim and works backwards to the endpoint, the sample, and the sites. A study designed around what can be demonstrated is more likely to succeed than one designed around what the sponsor wants to show.

Why nutraceutical studies fail at a higher rate than pharmaceutical trials

Clinical trials across all categories fail at a high rate. An estimated 50% do not meet their primary endpoint. For nutraceutical and consumer health studies, the proportion is likely higher. This is not because supplements and functional foods do not work. It is because nutraceutical clinical trial design often applies frameworks built for pharmaceutical drug development to a very different category of product.

Pharmaceutical drugs typically have large, measurable effects at clinically relevant doses. Their endpoints are often validated through decades of precedent in that specific indication. Effect size assumptions for sample size calculations have real-world comparators from previous trials. Nutraceuticals do not. When a nutraceutical sponsor borrows endpoint selection and power assumptions from a drug study, the study is calibrated around effects the product cannot realistically produce.

There is also a commercial dynamic that drives endpoint failures. Sponsors often need results that support marketing claims and product registration. This need creates pressure to frame endpoints ambitiously. An endpoint that would be compelling if met is not necessarily an endpoint the study can meet. When commercial ambition drives endpoint selection instead of scientific evidence, the study is set up to fail before the first participant is screened.

The three categories of nutraceutical clinical trial design failure

Endpoint failures in nutraceutical studies generally fall into three categories. The first is selection failure: the wrong endpoint was chosen. The second is powering failure: the right endpoint was chosen but the sample was not large enough to detect the effect. The third is operational failure: the endpoint was achievable in theory but was measured inconsistently in practice. Each category requires a different fix. A study that fails for all three reasons is not a study that can be salvaged at analysis.

For a broader view of the challenges nutraceutical sponsors face across their programs, see top 10 challenges in nutraceutical clinical trials.

Endpoint selection: the most common source of failure

Endpoint selection is where most nutraceutical studies go wrong. The failure typically comes from one of two directions. Either the endpoint is too ambitious and requires an effect size the product cannot plausibly generate at the dose studied. Or the endpoint is not specific enough to detect the product’s actual effect mechanism. Both problems can exist in the same protocol.

Sponsors often select endpoints because they are well-recognised in the clinical literature for that indication. For example, a study on a joint health supplement might choose DAS28 as the primary endpoint because it is standard in rheumatoid arthritis drug trials. However, DAS28 was designed to detect effects of disease-modifying therapies at clinical doses. A nutraceutical formulation is unlikely to produce changes on that scale. The endpoint is real, validated, and completely wrong for the product.

A more useful approach is to identify what the product’s active mechanism actually affects and find the most sensitive validated measure of that specific mechanism. This requires reviewing the evidence base for the active ingredients at the intended dose, not the broader indication literature. If no validated instrument measures the effect at the scale the product can produce, this is a signal to reconsider the claim before the protocol is finalised.

How regulatory context should shape nutraceutical clinical trial design endpoint choices

The regulatory standard the study needs to meet also determines what the endpoint must demonstrate. Health claim substantiation in the European Union operates under the EFSA scientific substantiation framework. This framework requires robust clinical evidence of a cause-and-effect relationship between the nutrient and the claimed effect. This is a high bar. Under FDA dietary supplement regulations, structure-function claims operate under a different and generally lower evidentiary standard. A study designed to meet EFSA substantiation requirements will typically be larger and more rigorously powered than one designed for FDA structure-function claim support.

Sponsors planning to use study results in multiple markets should therefore decide the regulatory destination before selecting the endpoint and the study design. An endpoint that is sufficient for a US structure-function claim may not provide the data EFSA needs. Designing the study to the higher standard from the start costs more but produces data usable in more markets. Retrofitting the protocol after the regulatory destination changes adds cost and often requires a separate study.

Sample size and power calculation errors

The second category of failure is underpowering. A study is underpowered when its sample size is not large enough to detect the effect of interest at the specified level of statistical significance. Underpowering means the study fails to reach its endpoint even if the product is genuinely effective. The result is a negative study that does not mean the product does not work. It means the study was not designed to show that it does.

Underpowering in nutraceutical studies typically traces to the effect size assumption used in the sample size calculation. That assumption determines how large the difference between the treated and control groups needs to be for the study to detect it. When sponsors borrow effect size assumptions from pharmaceutical trials, or from the most optimistic study in the literature, the calculation underestimates how many participants are needed. The study then runs, the effect is real but smaller than assumed, and the result is non-significant.

Conservative effect size assumptions are therefore essential in nutraceutical clinical trial design. When the evidence base is thin, the safest approach is to assume a smaller effect than the available literature suggests. This increases the required sample size. However, running a study that fails and generates nothing costs far more than running a slightly larger study that produces a usable result.

When overpowering is also a problem

Overpowering is less common but does occur in consumer health studies run by sponsors applying a pharmaceutical-scale design to a nutraceutical context. A study that is larger than necessary adds cost without improving the result. Many nutraceutical and consumer health sponsors run multiple studies per year to support a product claims pipeline. For these sponsors, overspending on any individual study has a direct budget impact across the program.

The goal is a sample that is adequate but not over-engineered. It should be large enough to detect the realistic effect at the chosen significance level. It should not require more resources than the study objective justifies. Reaching that balance requires an honest effect size assessment and a statistician experienced in the nutraceutical category. Applying pharmaceutical precedent by default produces the wrong sample.

Eligibility criteria and population mismatch

Eligibility criteria determine who is in the study. When those criteria are poorly calibrated to the product and the available population, they create two separate problems. Criteria that are too restrictive make recruitment slow. If few available participants meet the inclusion criteria, the study takes longer to fill and is more likely to remain underpowered throughout. Criteria that are too broad include a heterogeneous population. Individual variation then dilutes the treatment signal, making the effect harder to detect at the group level.

Consumer health studies face a specific version of this problem. Many nutraceutical products target generally healthy adults seeking to maintain or improve health. However, demonstrating a measurable effect in a healthy population is genuinely difficult. Effects are smaller in people who are not ill. The signal-to-noise ratio is worse. A study run in a healthy population therefore requires either a very large sample or a very sensitive endpoint. A very specific subgroup where the product’s effect is most likely to be visible is another option.

Matching eligibility criteria to recruitment reality

The right eligibility criteria come from an honest site feasibility process. Sites should be asked how many participants per month meet the specific proposed criteria. This is different from asking how many participants they see in the general target population. A site seeing 300 patients per month with joint complaints may have far fewer who meet the baseline score threshold. The prior supplement washout period can further reduce the eligible pool.

Early investigator engagement allows sponsors to test whether the eligibility criteria are operationally feasible before the protocol is locked. When investigators flag that the criteria exclude most of the available population, there is time to adjust. Once the protocol is approved and the study is running, changing eligibility criteria requires an amendment that resets timelines and may require regulatory re-review. Identifying the mismatch at feasibility costs days. Identifying it at Month 3 costs months.

Operational inconsistency: the failure mode that appears at analysis

The third category of failure is operational. A study can have the right endpoint, the right sample size, and the right population and still fail. Inconsistent measurement across sites is the cause. This failure mode does not become visible until the data are collected and the sponsor attempts to pool results across sites.

Nutraceutical and consumer health studies often use endpoints that require subjective assessment: quality of life instruments, dietary recall surveys, physical performance tests, and symptom scores. These measures are sensitive to how sites administer them. When different sites train staff differently, use different instrument versions, or allow participants to complete assessments under different conditions, the data cannot be reliably pooled.

What operational consistency requires in nutraceutical clinical trial design

Operational consistency requires standardised training for all site staff before the study opens. It requires a single, version-controlled assessment tool used identically at all sites. It also requires a data management plan that flags missing or inconsistent data early enough for sites to correct it. When study coordinators understand that endpoint data quality is a protocol compliance requirement, not just an administrative preference, measurement consistency improves.

Patient-reported outcome instruments present a specific challenge. Not all validated instruments are validated in all populations. A quality of life tool validated in a European population may perform differently in an APAC trial context. Sponsors using patient-reported outcomes should verify that the instrument is validated for the study population and the language in which it will be administered. Using an unvalidated translation reduces the defensibility of the endpoint results at analysis. For nutraceutical studies that include bioavailability components, see BA/BE studies for nutraceuticals for related design considerations.

What good nutraceutical clinical trial design looks like

A study designed to succeed starts with the claim. The claim defines what the study must demonstrate. The demonstration determines the endpoint. The endpoint, together with a realistic effect size estimate and an appropriate significance level, determines the sample size. Each step is constrained by the previous one. Sponsors who start with the desired result and work backwards tend to end up with studies that cannot deliver. Working forward from the evidence is the better approach.

Good nutraceutical clinical trial design also accounts for the target publication or regulatory destination from the beginning. If the sponsor intends to publish results in a peer-reviewed journal, the study should meet that journal’s requirements for methodology, sample size, and reporting transparency. The CONSORT framework provides a widely-used standard for reporting randomised trials. Studies designed with CONSORT reporting in mind tend to be stronger studies. The reporting requirements push sponsors to pre-specify endpoints, justify sample sizes, and document randomisation and blinding. This makes the results more credible.

Finally, good nutraceutical clinical trial design requires a CRO that distinguishes between pharmaceutical and consumer health study models. A CRO that defaults to pharmaceutical-scale design for a consumer health study, without asking what the claim is and what the evidence can support, is applying the wrong framework. The result is a study that is either over-engineered and too expensive, or mis-calibrated and likely to fail. The right design is the one that is smallest and simplest while still being capable of generating a result the sponsor can use.

Conclusion

Nutraceutical clinical trial design failures are common and, in most cases, preventable. The product is not always the problem. The endpoint chosen, the sample size assumed, the eligibility criteria set, and the operational standards applied all shape whether the study meets its primary objective. When these design decisions are made without reference to what the product can realistically demonstrate, failure is the predictable result. The available population, the proposed dose, and the measurement tool all need to be calibrated to the effect. A CRO with experience in nutraceutical clinical trial design reduces this risk. A CRO adapting a pharmaceutical model to a consumer health brief does not.

---

Designing a Nutraceutical or Consumer Health Study?

If you are scoping a nutraceutical or consumer health study, Credevo can help. We can pressure-test the endpoint selection, sample size assumptions, and eligibility criteria. Please fill out the form below to connect with our team.

---

Frequently asked questions

What is nutraceutical clinical trial design and why does it differ from pharmaceutical trial design?

Nutraceutical clinical trial design refers to the process of structuring a clinical study to evaluate a nutraceutical, dietary supplement, or consumer health product. It differs from pharmaceutical trial design because nutraceutical products typically produce smaller, more variable effects than drugs. Endpoint selection must be more sensitive. Effect size assumptions in sample size calculations must be more conservative. Eligibility criteria must be calibrated to the population where the effect is most detectable. A pharmaceutical CRO applying a drug trial framework to a nutraceutical study without adapting the design will typically produce a study that is over-powered or miscalibrated. Both outcomes waste resources.

How do I choose the right primary endpoint for a nutraceutical study?

Start with the claim you want to substantiate and identify the most direct, validated measure of that specific effect. The endpoint should be sensitive enough to detect changes at the scale the product can realistically produce at the intended dose. Review the evidence base for the active ingredients at that dose, not the broader indication literature from pharmaceutical trials. If the most well-recognised endpoint for that indication was designed to detect drug-level effects, it may not be appropriate for nutraceutical clinical trial design. A more sensitive or mechanism-specific measure may be more likely to show a real effect if one exists.

Why do so many nutraceutical trials fail to meet their primary endpoint?

Most endpoint failures in nutraceutical studies trace to design decisions made before the first participant enrolled. Common causes include endpoints too ambitious for the product’s realistic effect. Sample sizes calculated using overly optimistic effect size assumptions are another frequent problem. Eligibility criteria that exclude too many participants, or include too heterogeneous a population, also contribute. Operational inconsistency in how endpoints are measured across sites is a fourth cause. These failures are preventable. When nutraceutical clinical trial design starts with a realistic assessment of what the product can demonstrate, the study is more likely to produce a usable result. Starting from what the sponsor wants to show, rather than what the evidence supports, is the common mistake.

How should eligibility criteria be set in a nutraceutical study?

Eligibility criteria should reflect three things. First, the population where the product’s effect is most likely to be detectable. Second, the population the product is intended for commercially. Third, the population that is actually available at the proposed study sites. When these three do not align, the criteria need adjustment. Site feasibility should include a specific check. It should ask how many participants per month at each site meet the proposed criteria, not just how many fit the general diagnosis or demographic. This check should happen before the protocol is locked, when adjustments are still straightforward.

What role does the target journal or regulatory body play in nutraceutical clinical trial design?

The regulatory destination and publication target should shape the study design from the start. EFSA health claim substantiation requires robust clinical evidence of cause and effect, which generally means a larger, better-powered study with pre-specified endpoints. FDA structure-function claims operate under a lower evidentiary standard. If the sponsor plans to use results in both markets, the study should be designed to the higher standard. For journal publication, the study should be designed to meet the target journal’s requirements for methodology, sample size justification, and endpoint pre-specification. Designing a study around the publication or regulatory destination from the beginning produces more useful results. Retrofitting the evidence to a destination decided after the study runs is less effective.